DYAX
About Dyax
Dyax therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of inflammation and oncology.
Dyax's core proprietary phage display technology allows the rapid identification of compounds that bind with very high affinity and specificity to therapeutic targets. Utilizing phage display, they generate large diverse libraries of human antibodies, peptides, and proteins, which may be screened against disease-associated target molecules to identify potential binders. Automation allows us them rapidly screen these libraries for high-affinity binders. Their libraries' vast size and diversity often yield multiple candidates, from which they can quickly select the single best therapeutic candidate.
Product Pipeline Discovery Labs
Clinical Pipeline Dyax's therapeutic product pipeline contains fully human monoclonal antibodies, recombinant proteins and peptides. Dyax already has three clinical development programs involving two recombinant small proteins. The first, DX-88, is in clinical trials for the treatment of hereditary angioedema (HAE) in a joint venture with Genzyme Corporation. It is also being evaluated by Dyax alone in clinical trials for use during on-pump open heart surgery (CABG).
DX-890, Dyax's second compound in clinical development, is being evaluated by Dyax's collaborator Debiopharm SA for the treatment of cystic fibrosis (CF).
More on Dyax
Key
Statistics for Dyax
Basic
Chart for Dyax